Form 4: Cytek Biosciences Director Michael Holder Reports Stock Transactions

Director Michael Holder reports the acquisition and disposal of Cytek Biosciences common stock and restricted stock units on March 10, 2025.

Summary

• On March 10, 2025, Michael Holder, a director of Cytek Biosciences, Inc. (CTKB), reported transactions involving the company's common stock and Restricted Stock Units (RSUs).
• Holder acquired 2,908 shares of common stock and disposed of 6,543 shares.
• Following these transactions, Holder beneficially owns 19,635 derivative securities in the form of Restricted Stock Units (RSUs).
• The RSUs vest in installments on various dates, including August 18, November 18, March 10, and May 18 of each year, until fully vested.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It doesn't necessarily reflect a broader industry trend but is specific to the individual's holdings and transactions within Cytek Biosciences.

Stakeholder Impact

• Shareholders are informed about the trading activity of a company director, which can provide insights into insider sentiment, although this specific filing doesn't necessarily indicate a trend.

Key Dates